| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7259186 | ABBVIE | Salts of fenofibric acid and pharmaceutical formulations thereof |
Jan, 2025
(1 year, 3 months from now) | |
Trilipix is owned by Abbvie.
Trilipix contains Choline Fenofibrate.
Trilipix has a total of 1 drug patent out of which 0 drug patents have expired.
Trilipix was authorised for market use on 15 December, 2008.
Trilipix is available in capsule, delayed release;oral dosage forms.
The generics of Trilipix are possible to be released after 07 January, 2025.
Drugs and Companies using CHOLINE FENOFIBRATE ingredient
Market Authorisation Date: 15 December, 2008
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
How can I launch a generic of TRILIPIX before it's drug patent expiration?
More Information on Dosage
TRILIPIX family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic